Artrya Limited (ASX:AYA): Cardiac Imaging Software, Financial Position and US Commercialisation

Aditi Sarkar

21 October 2026 03:23 PM AEDT

Artrya Limited (ASX:AYA): Cardiac Imaging Software, Financial Position and US Commercialisation

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Artrya (ASX:AYA) develops AI-supported software for analysing coronary CT scans.
The December 2025 half-year net loss was AUD 10.743 million.
Cash and term deposits totalled AUD 76.670 million at 31 December 2025.
The company reported a capital raising of approximately AUD 80 million during the half-year.

Artrya Limited develops artificial-intelligence-based clinical decision-support software that helps clinicians assess coronary artery disease from coronary computed tomography angiography scans. Its Salix platform, US commercialisation activities and latest available interim financial statements place regulatory access, hospital integration and cash expenditure in focus. Artrya (ASX:AYA) was listed at AUD 2.585, up 1.77%, in the share-price figures supplied for the batch; those figures do not establish a verified trading date.

Company Business

Artrya’s software processes cardiac CT images to help clinicians assess coronary anatomy and characteristics of plaque in arteries. Its products are designed to support, rather than replace, clinician interpretation. The company describes the platform as AI-based diagnostic-support software on its official website.

Salix Coronary Anatomy forms part of the company’s suite of software products. The company also develops Coronary Plaque and Coronary Flow modules, which have separate clinical functions and regulatory considerations. Product clearance for one module should not be read as approval of every planned software capability.

Artrya (ASX:AYA) is headquartered in Western Australia, with commercial activities directed particularly towards the United States and Australia. Its intended customers include hospitals, radiology organisations and cardiology services that perform or interpret cardiac CT investigations. Implementation requires access to clinical imaging workflows and suitable systems integration.

Recent Development

In February 2026, Artrya issued its half-year financial report for the six months ended 31 December 2025. The company described spending on US customer activities, regulatory work and development of the Salix Coronary Plaque and Flow modules. Commercial activity in this period remained distinct from established recurring profitability.

The interim report stated that proceeds from an approximately AUD 80 million equity raising were intended for the US rollout, hospital-group adoption and the SAPPHIRE clinical study. That study is part of the company’s programme to develop clinical evidence relating to coronary artery disease assessment and treatment decisions.

Artrya (ASX:AYA) reported that the financial period included commercial work with US customers as well as development and regulatory expenditure. The scale and timing of commercial revenue depend on hospital onboarding, clinical use, reimbursement arrangements and the regulatory status of particular software modules.

Financial Performance and Sector Context

The group reported a statutory net loss of AUD 10.743 million for the December 2025 half-year, compared with AUD 7.441 million in the corresponding prior period. The increase reflected expansion expenditure and included a AUD 2.223 million non-cash charge associated with foundation-partner affiliate options, as disclosed by the company.

Cash and cash equivalents were AUD 46.521 million on 31 December 2025. A further AUD 30.149 million of bank term deposits were recorded as investments, giving combined cash and term deposits of AUD 76.670 million. These figures should not be confused with sales or operating cash generation.

Net cash used in operating activities during the six months was AUD 10.877 million. Receipts from customers and employees were AUD 66,000, while payments to suppliers and employees totalled AUD 11.413 million. Net financing cash inflow of AUD 76.154 million largely reflected the placement and option exercises.

For Artrya (ASX:AYA), the difference between financing inflows and operating receipts is central to assessing financial development. Raising equity expands available funding but does not itself show that the software has achieved a sustainable level of customer demand. Subsequent quarterly cash flow disclosures are therefore relevant to monitoring deployment expenditure and receipts.

The sector operates within medical-device software regulation, clinical validation requirements and hospital procurement processes. In the United States, individual regulatory clearances, integration with hospital systems and reimbursement processes can each affect the pace of deployment. Australian clinical use likewise depends on applicable product registrations and customer adoption.

Risks to Consider

Commercialisation introduces dependence on hospital procurement timelines, implementation resources and clinical workflow changes. The timing of regulatory decisions for individual modules may differ from product-development schedules. Research and commercial staffing, customer support and software validation also create costs before material recurring receipts are established.

Software used with patient imaging data requires cybersecurity controls, privacy protections and dependable performance. Clinical claims need evidence consistent with relevant regulatory permissions. The company also faces potential equity dilution when new shares or performance instruments are issued.

What to Watch Next

Key disclosures to monitor include new quarterly cash flow reports, confirmed hospital implementations, customer receipts and any formal regulatory announcements relating to Salix modules. Clinical evidence produced through the SAPPHIRE programme may also inform future medical use and commercial discussions, without determining their outcome.

Artrya (ASX:AYA) can be assessed through actual contract performance and collection of recurring fees rather than headline agreement values alone. Future statutory results will show the relationship between software revenue, operating expenditure, non-cash charges and available funding.

Key Insights

Artrya has a defined AI-supported cardiac imaging product line and has been funding US commercial activity alongside regulatory and clinical work. The December 2025 interim figures show a sizeable financing position but limited customer receipts and a statutory loss. The next meaningful indicators are verified deployments, regulatory milestones, revenue recognition and operating cash requirements.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.